124 related articles for article (PubMed ID: 10134327)
1. Virginia okays coverage for experimental cancer coverage.
Tokarski C
J Am Health Policy; 1994; 4(3):57-8. PubMed ID: 10134327
[No Abstract] [Full Text] [Related]
2. Experimental medical treatments: who should decide coverage?
Collins JC
Spec Law Dig Health Care Law; 1998 Jan; (226):9-45. PubMed ID: 10176412
[No Abstract] [Full Text] [Related]
3. Mandates for unproven health care interventions.
Gervais KG; Priester R
Minn Med; 1996 Apr; 79(4):52-5. PubMed ID: 8637495
[No Abstract] [Full Text] [Related]
4. When an insurer calls your treatment experimental.
Holoweiko M
Med Econ; 1995 Sep; 72(17):171-2, 175-6, 178-82. PubMed ID: 10151340
[No Abstract] [Full Text] [Related]
5. 3rd Circuit keeps split alive on autologous bone marrow transplants for breast cancer. Clark v. K-Mart Corporation.
Margolis RE
Healthspan; 1992; 9(7):21-2. PubMed ID: 10183724
[No Abstract] [Full Text] [Related]
6. Health insurance oversight issue brief: mandated benefits: breast cancer screening coverage requirements: year end report--2004.
Plaza CI
Issue Brief Health Policy Track Serv; 2004 Dec; ():1-11. PubMed ID: 15726740
[No Abstract] [Full Text] [Related]
7. Experimental treatment: can you do the right thing without going broke?
Holoweiko M
Bus Health; 1995 May; 13(5):38-40, 45-6, 48. PubMed ID: 10164496
[No Abstract] [Full Text] [Related]
8. How courts view experimental treatments.
Gallinari KL
J Health Care Benefits; 1994; 3(5):37-43. PubMed ID: 10133661
[TBL] [Abstract][Full Text] [Related]
9. Finance issue brief: mandated benefits: breast cancer screening coverage requirements: year end report-2003.
Plaza CI
Issue Brief Health Policy Track Serv; 2003 Dec; ():1-11. PubMed ID: 14974439
[No Abstract] [Full Text] [Related]
10. Blues panel: marrow transplants effective in advanced breast cancer.
Scott L
Mod Healthc; 1996 Mar; 26(10):4. PubMed ID: 10156330
[No Abstract] [Full Text] [Related]
11. Experimental treatment being covered.
Cowans DS
Mod Healthc; 1996 Jun; 26(25):56. PubMed ID: 10158007
[No Abstract] [Full Text] [Related]
12. Health insurance oversight: mandated benefits issue brief: prostate cancer screening coverage requirements: year end report--2004.
Plaza CI
Issue Brief Health Policy Track Serv; 2004 Dec; ():1-5. PubMed ID: 15726731
[No Abstract] [Full Text] [Related]
13. New rules on therapy only fuel dispute.
Scott L
Mod Healthc; 1994 May; 24(20):6, 13. PubMed ID: 10133524
[No Abstract] [Full Text] [Related]
14. The mandate for investigational cancer therapies.
Brown E
Physician Exec; 1995 Sep; 21(9):46-7. PubMed ID: 10151483
[TBL] [Abstract][Full Text] [Related]
15. Defining experimental therapy--a third-party payer's dilemma.
Newcomer LN
N Engl J Med; 1990 Dec; 323(24):1702-4. PubMed ID: 2233969
[No Abstract] [Full Text] [Related]
16. Finance issue brief: mandated benefits: osteoporosis coverage requirements: year end report-2003.
Plaza CI
Issue Brief Health Policy Track Serv; 2003 Dec; ():1-4. PubMed ID: 14870744
[No Abstract] [Full Text] [Related]
17. Finance issue brief: mandated benefits: colorectal cancer screening coverage requirements: year end report-2003.
Plaza CI; Rane S
Issue Brief Health Policy Track Serv; 2003 Dec; ():1-5. PubMed ID: 14870753
[No Abstract] [Full Text] [Related]
18. Employer coverage of experimental medical procedures.
Mora J
Health Cost Manage; 1986; 3(5):17-25. PubMed ID: 10279242
[TBL] [Abstract][Full Text] [Related]
19. Coverage decisions in a high-tech world.
Nazametz P
Bus Health; 1987 Aug; 4(10):12-3. PubMed ID: 10282932
[No Abstract] [Full Text] [Related]
20. State legislative approaches to regulating coverage for experimental procedures.
Reagan ME
Health Care Law Newsl; 1994 Sep; 9(9):13-6. PubMed ID: 10136999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
